Get Access Now: Car t Cell Therapy for Aggressive Non-Hodgkin Lymphoma
November 17, 2017
| by City of Hope
CAR T Expertise and Ongoing Research at City of Hope
City of Hope, a world-renowned cancer research and treatment center, is now accepting patients
for the first-ever FDA-approved CAR T cell therapy
for adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. City of Hope is the only Southern California designated center and one of only a few in the nation to offer axicabtagene ciloleucel (axi-cel). Axi-cel has been found to be effective in treating non-Hodgkin lymphoma (NHL), one of the most common and difficult-to-treat forms of blood cancer in the U.S.
Axi-cel is a unique product of Kite Pharma that consists of using a patient’s re-engineered T cells to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein that can be found on the surface of NHL cells. The FDA approval of axi-cel is supported by data from the ZUMA-1 phase 2 trial, for which City of Hope was one of four initial trial centers.
The key to City of Hope’s success in advancing lifesaving CAR T cell therapy is our legacy of patient-centered care — treating not just the illness, but caring for the entire patient. City of Hope has the expertise, knowledge and highly trained staff to successfully deliver axicabtagene ciloleucel to patients while continuing to advance clinical trials for additional CAR T therapies to save even more lives."Stephen J. Forman, M.D.
City of Hope is exceptionally positioned to begin offering this groundbreaking, potentially lifesaving new treatment for adult patients with large B-cell lymphoma. A pioneer in the CAR T field, more than 150 patients have been treated in CAR T therapy trials at City of Hope, and the institution was the first to introduce CAR T clinical trials in acute myeloid leukemia and glioblastoma, an aggressive brain tumor. It currently maintains 13 ongoing clinical trials with an additional nine in the pipeline for 2018. City of Hope is one of only a few research institutions capable of harnessing the comprehensive "bench to bedside" resources necessary for the discovery, translational research, development, manufacturing, quality assurance, and delivery of this leading-edge treatment.
, Thank you for subscribing to Physician News.
Check your inbox for the latest breakthroughs, clinical trials, and CME opportunities.
, Unable to process your request. We're sorry for the inconvenience. Please try after sometime.